Polyrizon announced its national phase patent application for innovative nasal hydrogel technologies, enhancing drug delivery and protection.
Quiver AI Summary
Polyrizon Ltd., a biotech company based in Raanana, Israel, announced the publication of a national phase patent application by the USPTO for its innovative intranasal hydrogel technologies. These include the Capture and Contain (C&C™) platform, which establishes a barrier against airborne biological threats, and the Trap and Target (T&T™) system, which is designed for effective nasal drug delivery. The C&C technology is developed as a nasal spray to protect against viruses and allergens, while T&T focuses on enhancing the delivery of pharmaceuticals via the nasal cavity. Polyrizon is committed to advancing these technologies for various medical applications, as detailed in their press release.
Potential Positives
- Publication of a national phase patent application by the USPTO signifies a critical step in securing intellectual property for Polyrizon's innovative technologies.
- The C&C™ and T&T™ platforms represent cutting-edge advancements in nasal drug delivery and protection, potentially positioning Polyrizon as a leader in this niche biotech sector.
- The innovative hydrogel technology may offer significant competitive advantages in addressing airborne biological threats and enhancing drug efficacy, broadening market opportunities for the company.
Potential Negatives
- The company is in a development stage, which may raise concerns regarding its capability to bring products to market effectively.
- The reliance on forward-looking statements suggests uncertainty in the company's projections, potentially leading to a lack of investor confidence.
- The continued development of technologies that are still in pre-clinical stages may indicate a slower path to commercialization and revenue generation.
FAQ
What patent application did Polyrizon recently announce?
Polyrizon announced the publication of a national phase patent application encompassing its Capture and Contain (C&C™) and Trap and Target (T&T™) platform technologies.
What are Polyrizon's core technologies?
Polyrizon's core technologies are Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), an advanced nasal drug delivery system.
How does the C&C™ technology work?
The C&C™ technology forms a physical barrier in the nasal cavity that captures airborne biological threats, preventing them from penetrating the body.
What is the purpose of the T&T™ platform?
The T&T™ platform is designed for prolonged residence time and targeted delivery of medications to enhance therapeutic efficacy in nasal drug delivery.
How does Polyrizon deliver its hydrogel technology?
Polyrizon delivers its hydrogel technology in the form of nasal sprays, creating a thin, protective hydrogel-based barrier in the nasal cavity.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the United States Patent and Trademark Office (“USPTO”). The patent application encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. Both technologies represent Polyrizon's commitment to creating innovative solutions for protecting and treating via the nasal cavity.
Polyrizon Technologies: Advanced Drug Delivery and Protection Platforms
Polyrizon’s innovative Capture and Contain (C&C™) platform utilizes a natural 3D polymeric network engineered to adhere optimally to the nasal mucosa. This advanced network forms a physical barrier that captures and contains airborne biological threats, such as allergens, viruses, and molds, preventing their penetration and protecting the body.
In addition, Polyrizon’s T&T platform is a novel drug delivery system designed for prolonged residence time and close contact with mucosal tissues, ensuring highly effective and targeted delivery of medications. Developed by drug delivery experts, the T&T platform can be customized to meet the unique requirements of different molecules, enhancing therapeutic efficacy and enabling a wide range of medical applications.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain
TM
, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit
https://polyrizon-biotech.com
.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its commitment to creating innovative solutions for protecting and treating via the nasal cavity. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s prospectus (Registration No. 333-266745), dated October 24, 2024 and filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
